Neuromyelitis optica spectrum disorder | news | blogs | iPharmaCenter

October 12, 2022

AstraZeneca announced strong efficacy data of Ultomiris.

AstraZeneca announced the results of the CHAMPION-NMOSD trial of Ultomiris (ravulizumab) in patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD).

AstraZeneca announced that the results were exceptional; after a median treatment duration of 73 weeks, there were zero relapses. Further, the company announced that it would present the results at the ECTRIMS congress.

AstraZeneca has received global rights of Ultomiris following the acquisition of Alexion by AstraZeneca in 2021. With the acquisition, AstraZeneca expanded its portfolio into rare diseases.